Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Wondering whether Iovance Biotherapeutics at US$3.80 is pricing in its prospects fairly, or if the market is missing something important about this stock's value. The share price has a mixed return profile, with a 50.8% gain year to date and 24.2% over the last year, alongside multi year returns of a 32.3% decline over three years and an 87.8% decline over five years. Recent coverage has focused on how the stock's strong year to date performance sits against its weaker multi year track record. This has prompted questions about whether recent optimism reflects a change in how investors view the company's risk and potential. At the same time, the article you are reading was triggered to provide evergreen coverage, so the goal is to step back and assess valuation using consistent, repeatable methods rather than reacting only to short term moves. Iovance Biotherapeutics currently has a valuation score of 4 out of 6 , which means it screens as undervalued against several checks. Nex
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Iovance Biotherapeutics (IOVA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.MarketBeat
- Iovance Biotherapeutics (IOVA) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback [Seeking Alpha]Seeking Alpha
- Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help [Seeking Alpha]Seeking Alpha
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 4/17/26 - Form PRE
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- IOVA's page on the SEC website